That rapid and significant CRP decline can be explained by the pharmacodynamic role of the anti-IL6-receptor (R) [13] in inhibiting the hepatic production of inflammatory proteins during the acute phase of RA. The gene discussed is CRP; the disease is rheumatoid arthritis.